What can we help you with?

Services Phases

Services

Non-Covalent Binding AssaysNon-Covalent Binding AssaysCovalent Binding AssaysCovalent Binding AssaysProteomics & ChemoproteomicsProteomics & ChemoproteomicsSmall Molecule AnalysisSmall Molecule AnalysisOligo AnalysisOligo AnalysisData ProductsData ProductsView All ServicesView All Services

Phases

Target Discovery & ValidationTarget Discovery & ValidationLead GenerationLead GenerationLead Selection & OptimizationLead Selection & OptimizationPreclinical StudiesPreclinical StudiesBiomarker Discovery, Development & AnalysisBiomarker Discovery, Development & AnalysisView All PhasesView All Phases

What can we help you with?

Modalities Therapeutic Areas

Modalities

RadiotherapeuticsRadiotherapeuticsMolecular GluesMolecular GluesTargeted DegradersTargeted DegradersCovalent DrugsCovalent DrugsDNA- and RNA-Targeting DrugsDNA- and RNA-Targeting DrugsOligonucleotide TherapeuticsOligonucleotide TherapeuticsKinase InhibitorsKinase InhibitorsView All ModalitiesView All Modalities

Therapeutic Areas

OncologyOncologyImmunologyImmunologyNeuroscienceNeuroscienceMetabolic DiseaseMetabolic DiseaseInfectious DiseaseInfectious DiseaseRare DiseasesRare DiseasesView All Therapeutic AreasView All Therapeutic Areas

What can we help you with?

TechnologiesOmicscouts Platforms Expertise

TechnologiesOmicscouts

ProteomeScout™ProteomeScout™PlasmaScout™PlasmaScout™QuantScout™QuantScout™TurnoverScout™TurnoverScout™Protein Turnover Atlas™Protein Turnover Atlas™SignalingScout™SignalingScout™UbiScout™UbiScout™DecryptMDecryptMTargetScout™TargetScout™PhotoTargetScout™PhotoTargetScout™KinomeScout™KinomeScout™CysScout™CysScout™SideScout™SideScout™NucleoBeads™NucleoBeads™SurfaceScout™SurfaceScout™View All TechnologiesView All Technologies

Platforms

RapidFire-MSRapidFire-MSICP-MSICP-MSOrbitrap Astral ZoomOrbitrap Astral ZoomOrbitrap AscendOrbitrap AscendView All PlatformsView All Platforms

Expertise

Project ManagementProject ManagementCompound Management & Chemical LibrariesCompound Management & Chemical LibrariesScreening LaboratoryScreening LaboratoryBiochemistry & Chemical BiologyBiochemistry & Chemical BiologyCell & Molecular BiologyCell & Molecular BiologyMS-based ProteomicsMS-based ProteomicsComputational BiologyComputational BiologyView All ExpertiseView All Areas of Expertise

Oligonucleotide Therapeutics

Modulate protein expression and splicing with RNA-binding ASOs and RNAi

Submit a project inquiry

Support for the discovery and development of antisense therapeutics

Oligonucleotide therapeutics, including antisense oligonucleotides (ASOs) and RNA interference (RNAi), represent a powerful modality for the treatment of many diseases, particularly genetic disorders associated with aberrant protein production. The most famous example of oligonucleotide-based intervention is in the treatment of the neuromuscular disorder spinal muscular atrophy (SMA), associated with mutations in the SMN1 gene. Treatment with an ASO induces alternate splicing of the SMN2 transcript, leading to the generation of SMN protein that functionally replaces the missing SMN1 product.

The efficacy of this approach has led to continuing interest in this therapeutic modality. Our services can support the selection of optimal ASO/RNAi targets, the analysis of oligo species, and the comprehensive characterization of oligonucleotide treatment effects.

  • Identify targets amenable to ASO/RNAi intervention
  • Validate oligo identity and quality
  • Evaluate the effects of ASO/RNAi treatment on a proteome-wide level (e.g., measure protein level changes and protein synthesis rates, identify off-targets, and unambiguously determine splicing isoforms on protein level)

How we can help

  • Protein Turnover Atlas™

    This data product provides protein half-life data for over 16,000 proteins across almost 50 cell lines. By leveraging this data, researchers can evaluate suitable targets for covalent inhibition.

  • ProteomeScout™

    This technology provides deep proteome profiling at scale for the comprehensive characterization of molecular glues and other modalities. Our robust workflows and rapid turnaround times support iterative development of optimized molecular glue therapeutics.

  • QuantScout™

    Targeted quantitative proteomics enables the detection of target proteins and protein isoforms with superior accuracy and sensitivity, providing critical confirmation of gene therapy efficacy. This technology also facilitates immune profiling to ensure gene therapies can be delivered safely and effectively.

  • CysScout™

    This powerful chemoproteomic assay enables the quantitative assessment of reactive cysteine residues from live cells or cell extracts, providing critical support for target identification/deconvolution as well as engagement and selectivity profiling.

  • SurfaceScout™

    Comprehensive profiling of the cell surface proteome facilitates the discovery of target-specific cell surface antigens that can be used to direct ADC delivery and promote internalization.

  • Oligo Analysis

    Our quantification and analysis services can be applied to a wide range of oligos, enabling their effective characterization. In particular, we can perform adduct mapping via sequencing to identify site-specific modifications of DNA and RNA species.

Explore Other Modalities

We offer support for the development of a broad range of therapeutic modalities.

  • Kinase Inhibitors

    Develop selective and potent protein kinase inhibitors

  • ADCs

    Targeted immunotherapeutics for cancer treatment and beyond

  • Gene Therapies

    Modify genetic content and expression to enable new frontiers of disease treatment

  • Cell Therapies

    Harness the power of cell therapy to overcome unmet disease challenges

  • Radiotherapeutics

    Harness the ultra-sensitive analytic power of ICP-MS for radioligand discovery and development

  • Molecular Glues

    Induce or stabilize protein-protein interactions for therapeutic applications

  • Targeted Degraders

    Induce target degradation with precision and potency

  • Covalent Drugs

    Unlock potent and selective therapeutics through covalent binding

  • DNA- and RNA-Targeting Drugs

    Accelerate the development of DNA- and RNA-targeted small-molecule therapeutics

Submit a Project Inquiry

To connect with our scientific team, submit a project inquiry. Our team will be in touch shortly to schedule an introductory meeting.

Locations

United States

3 Federal Street, Suite 300
Billerica, MA 01821

Europe

Lise-Meitner-Strasse 30,
85354 Freising, Germany

Newsletter Signup

Sign up for News & Updates